Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with Methotrexate
Crossref DOI link: https://doi.org/10.1007/s12325-016-0372-z
Published Online: 2016-07-04
Published Print: 2016-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Batticciotto, Alberto
Ravasio, Roberto
Riva, Marta
Sarzi-Puttini, Piercarlo
Funding for this research was provided by:
Roche SpA